Standout Papers
- Adult eczema prevalence and associations with asthma and other health and demographic factors: A US population–based study (2013)
- Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis (2018)
- Global Skin Disease Morbidity and Mortality (2017)
- Patient burden and quality of life in atopic dermatitis in US adults (2018)
- Treatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb (2018)
- Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis (2021)
- Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis (2020)
- Atopic Dermatitis in America Study: A Cross-Sectional Study Examining the Prevalence and Disease Burden of Atopic Dermatitis in the US Adult Population (2018)
- Increasing Comorbidities Suggest that Atopic Dermatitis Is a Systemic Disorder (2016)
- Public Health Burden and Epidemiology of Atopic Dermatitis (2017)
- Comorbidities and the impact of atopic dermatitis (2019)
- Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial (2019)
- Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial (2021)
- Atopic dermatitis in the pediatric population (2021)
- Tralokinumab plus topical corticosteroids for the treatment of moderate‐to‐severe atopic dermatitis: results from the double‐blind, randomized, multicentre, placebo‐controlled phase III ECZTRA 3 trial* (2020)
- Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis (2023)
- Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies (2023)
- Guidelines of care for the management of atopic dermatitis in adults with topical therapies (2023)
Immediate Impact
7 from Science/Nature 112 standout
Citing Papers
GZMK-expressing CD8+ T cells promote recurrent airway inflammatory diseases
2025 StandoutNature
Atopic dermatitis
2025 Standout
Works of Jonathan I. Silverberg being referenced
Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials
2024
Comorbidities of atopic dermatitis—what does the evidence say?
2023
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Jonathan I. Silverberg | 18207 | 13330 | 6679 | 753 | 22.4k | |
| Johannes Ring | 14552 | 16613 | 7824 | 707 | 30.3k | |
| Jon M. Hanifin | 13754 | 10762 | 5266 | 245 | 18.7k | |
| Jacob P. Thyssen | 13820 | 7269 | 2591 | 634 | 18.1k | |
| Gil Yosipovitch | 10003 | 4215 | 2889 | 457 | 13.3k | |
| Alan D. Irvine | 11158 | 8114 | 3699 | 292 | 16.6k | |
| Sonja Ständer | 9756 | 4005 | 2788 | 427 | 13.3k | |
| Masutaka Furue | 7738 | 3666 | 2683 | 722 | 16.7k | |
| A.Y. Finlay | 14495 | 4423 | 2570 | 269 | 21.5k | |
| Giampiero Girolomoni | 9588 | 3720 | 3102 | 539 | 23.0k | |
| Lawrence F. Eichenfield | 8376 | 5100 | 2007 | 432 | 11.5k |
All Works
Login with ORCID to disown or claim papers
Loading papers...